Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Arvinas, Inc. ARVN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
61/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.80
+7.3%

Arvinas, Inc. (ARVN) is a Biotechnology company in the Healthcare sector, currently trading at $11.00. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is ARVN = $12 (+7.3% upside).

Valuation: ARVN trades at a trailing Price-to-Earnings (P/E) of -9 (S&P 500 average ~25).

Financials: revenue is $263M, +65%/yr average growth. Net income is $81M (loss), growing at +23.4%/yr. Net profit margin is -30.8% (negative). Gross margin is 98% (+4.2 pp trend).

Balance sheet: total debt is $9M against $434M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 4.92 (strong liquidity). Debt-to-assets is 1.2%. Total assets: $718M.

Analyst outlook: 20 / 26 analysts rate ARVN as buy (77%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 64/100 (Partial), Future 73/100 (Pass), Income 10/100 (Fail).

$11.80
▲ 7.27% Upside
Average Price Target
Based on 26 Wall Street analysts offering 12-month price targets for Arvinas, Inc., the average price target is $11.80, with a high forecast of $18.00, and a low forecast of $6.00.
Highest Price Target
$18.00
Average Price Target
$11.80
Lowest Price Target
$6.00

ARVN SharesGrow Score Overview

71/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 78/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 64/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ARVN

✓
VALUE Pass
78/100
ARVN trades at a trailing Price-to-Earnings (P/E) of -9 (S&P 500 average ~25). Forward PEG -1.26 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.18. Analyst consensus target is $12, implying +9.1% from the current price $11. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
ARVN: +65%/yr revenue is, +23.4%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ARVN: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 4.92 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
64/100
ARVN: Gross margin is 98% (+4.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 64/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 20 / 26 analysts rate ARVN as buy (77%). Analyst consensus target is $12 (+9.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ARVN: Net profit margin is -30.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range5.9-14.51
Volume830.07K
Avg Volume (30D)928.75K
Market Cap$706.47M
Beta (1Y)1.98
Share Statistics
EPS (TTM)-1.28
Shares Outstanding$64.9M
IPO Date2018-09-27
Employees430
CEORandy Teel
Financial Highlights & Ratios
Revenue (TTM)$262.6M
Gross Profit$257.4M
EBITDA$-75.3M
Net Income$-80.8M
Operating Income$-114.9M
Total Cash$685.4M
Total Debt$8.5M
Net Debt$-134.4M
Total Assets$717.9M
Price / Earnings (P/E)-8.6
Price / Sales (P/S)2.69
Analyst Forecast
1Y Price Target$11.00
Target High$18.00
Target Low$6.00
Upside0.0%
Rating ConsensusBuy
Analysts Covering26
Buy 77% Hold 19% Sell 4%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS04335A1051

Price Chart

Track all markets on TradingView
ARVN
Arvinas, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
5.90 52WK RANGE 14.51

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 RARE
RARE
Ultragenyx Pharmaceutical Inc.
$24.57
+3.98%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 NRIX
NRIX
Nurix Therapeutics, Inc.
$16.30
+2.45%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message